Logo image
Intravesical Dimethyl Sulfoxide Inhibits Acute and Chronic Bladder Inflammation in Transgenic Experimental Autoimmune Cystitis Models
Journal article   Open access

Intravesical Dimethyl Sulfoxide Inhibits Acute and Chronic Bladder Inflammation in Transgenic Experimental Autoimmune Cystitis Models

Ronald Kim, Wujiang Liu, Xiaohong Chen, Karl J. Kreder and Yi Luo
Journal of biomedicine & biotechnology, Vol.2011, pp.937061-9
01/01/2011
DOI: 10.1155/2011/937061
PMCID: PMC2989383
PMID: 21113298
url
https://doi.org/10.1155/2011/937061View
Published (Version of record) Open Access

Abstract

New animal models are greatly needed in interstitial cystitis/painful bladder syndrome (IC/PBS) research. We recently developed a novel transgenic cystitis model (URO-OVA mice) that mimics certain key aspects of IC/PBS pathophysiology. This paper aimed to determine whether URO-OVA cystitis model was responsive to intravesical dimethyl sulfoxide (DMSO) and if so identify the mechanisms of DMSO action. URO-OVA mice developed acute cystitis upon adoptive transfer of OVA-specific OT-I splenocytes. Compared to PBS-treated bladders, the bladders treated with 50% DMSO exhibited markedly reduced bladder histopathology and expression of various inflammatory factor mRNAs. Intravesical DMSO treatment also effectively inhibited bladder inflammation in a spontaneous chronic cystitis model (URO-OVA/OT-I mice). Studies further revealed that DMSO could impair effector T cells in a dose-dependent manner in vitro. Taken together, our results suggest that intravesical DMSO improves the bladder histopathology of IC/PBS patients because of its ability to interfere with multiple inflammatory and bladder cell types.
Biotechnology & Applied Microbiology Life Sciences & Biomedicine Medicine, Research & Experimental Research & Experimental Medicine Science & Technology

Details

Metrics

29 readers on Mendeley
Logo image